Memarzadeh Ezatollah, Heidari-Soureshjani Saeid
Department of Ophthalmology, School of Medicine, Kashani Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
J Ophthalmol. 2022 May 9;2022:8564818. doi: 10.1155/2022/8564818. eCollection 2022.
Web of Science, PubMed, and Scopus databases were searched for articles that addressed the relationship between statin consumption and risk of AMD. The pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. Cochran's test and the I statistic were used to evaluate the heterogeneity. To assess potential publication bias, Begg's test was used.
In total, 22 studies were reviewed in the meta-analysis that included 2063195 participants and 313702 (15.20%) AMD patients compared to individuals not receiving statins. The OR of AMD in statin-receiving participants was 0.93 (95% CI; 0.83-1.05, =0.225). The OR of AMD in those that received statins was 0.92 (95% CI; 0.75-1.13, =0.440) in case-control studies, 0.95 (95% CI; 0.82-1.09, =0.458) in cohort studies, 0.951 (95% CI; 0.59-1.53, =0.831) in cross-sectional studies, 0.94 (95% CI; 0.80-1.10, =0.468) in North America, 0.81 (95% CI; 0.54-1.21, =0.308) in Europe, 1.05 (95% CI; 0.94-1.18, =0.362) in Asia, and 0.52 (95% CI; 0.26-1.04, =0.125) in Australia. No publication bias was observed in this study (=0.114).
According to the results of this study, taking statins does not increase or decrease the risk of AMD development. Therefore, this drug group cannot be considered a protective or risk factor for the occurrence of AMD.
在科学网、PubMed和Scopus数据库中检索探讨他汀类药物使用与年龄相关性黄斑变性（AMD）风险之间关系的文章。采用随机效应模型计算合并比值比（OR）和95%置信区间（CI）。还进行了亚组分析和敏感性分析。使用Cochran's检验和I统计量评估异质性。为评估潜在的发表偏倚，采用了Begg检验。
在该荟萃分析中，总共审查了22项研究，这些研究纳入了2063195名参与者，与未接受他汀类药物的个体相比，有313702名（15.20%）AMD患者。接受他汀类药物治疗的参与者患AMD的OR为0.93（95%CI：0.83 - 1.05，I² = 0.225）。在病例对照研究中，接受他汀类药物治疗者患AMD的OR为0.92（95%CI：0.75 - 1.13，I² = 0.440），队列研究中为0.95（95%CI：0.82 - 1.09，I² = 0.458），横断面研究中为0.951（95%CI：0.59 - 1.53，I² = 0.831），北美地区为0.94（95%CI：0.80 - 1.10，I² = 0.468），欧洲为0.81（95%CI：0.54 - 1.21，I² = 0.308），亚洲为1.05（95%CI：0.94 - 1.18，I² = 0.362），澳大利亚为0.52（95%CI：0.26 - 1.04，I² = 0.125）。本研究未观察到发表偏倚（P = 0.114）。
根据本研究结果，服用他汀类药物不会增加或降低患AMD的风险。因此，该药物组不能被视为AMD发生的保护因素或风险因素。
